BioNTech Defies Sector Downturn with Strategic Oncology Pivot

In a year marked by significant revenue declines for major players in the mRNA and COVID-19 vaccine space, BioNTech SE bucked the trend. The company reported a 4.3% increase in annual revenue for the 2025 fiscal year, reaching €2.87 billion. This performance distinguishes BioNTech as the sole entity among the three leading COVID-19 vaccine developers to achieve positive year-over-year growth.

A Robust Financial Position Fuels Ambitious R&D Plans

The company’s financial strength was underscored by a particularly strong fourth quarter in 2025. Quarterly revenue of €907 million substantially exceeded market expert consensus estimates of €759 million. Furthermore, BioNTech concluded the year with a substantial war chest of €17.2 billion in liquid assets and securities, providing a significant buffer for its strategic initiatives.

Management’s outlook for 2026, however, anticipates a noticeable shift. Revenue is projected to fall within a range of €2.0 billion to €2.3 billion. Concurrently, the company plans to channel between €2.2 billion and €2.5 billion into research and development—an investment that surpasses its expected top-line figure. This deliberate allocation signals a clear strategy: capital amassed during the vaccine era is being systematically redirected to build a comprehensive oncology pipeline.

Should investors sell immediately? Or is it worth buying BioNTech?

Oncology Pipeline Takes Center Stage with Lung Cancer Focus

The strategic core of this transition is a focused push in oncology, with lung cancer treatments leading the charge. The most prominent candidate is pumitamig (BNT327), a bispecific antibody designed to simultaneously target PD-L1 and VEGF-A. Clinical data presented at the 2026 European Lung Cancer Congress demonstrated the compound’s antitumor activity across various lung cancer types, irrespective of patients’ PD-L1 expression levels.

Building on these findings, two global clinical trials are now underway. The ROSETTA Lung-01 study is a pivotal Phase 3 trial for advanced-stage small cell lung cancer, while ROSETTA Lung-02 is a Phase 2/3 trial for non-small cell lung cancer. Complementing this effort is BNT326, a HER3-directed antibody-drug conjugate, which has shown initial clinical data with a manageable safety profile in patients with metastatic non-small cell lung cancer.

BioNTech’s stated objective is to have a total of 15 active Phase 3 trials in oncology by the end of 2026. Several late-stage data readouts are expected within the same year, forming the basis for potential regulatory submissions. To support this ambitious clinical agenda while managing costs, the company has budgeted €700 million to €800 million for administrative expenses in 2026, maintaining a disciplined approach to overhead.